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Abstract
Resolution of inflammation is an active temporally orchestrated process demonstrated by the biosynthesis of novel
proresolving mediators. Dysregulation of resolution pathways may underlie prevalent human inflammatory diseases such as
cardiovascular diseases and periodontitis. Localized Aggressive Periodontitis (LAP) is an early onset, rapidly progressing
form of inflammatory periodontal disease. Here, we report increased surface P-selectin on circulating LAP platelets, and
elevated integrin (CD18) surface expression on neutrophils and monocytes compared to healthy, asymptomatic controls.
Significantly more platelet-neutrophil and platelet-monocyte aggregates were identified in circulating whole blood of LAP
patients compared with asymptomatic controls. LAP whole blood generates increased pro-inflammatory LTB4 with addition
of divalent cation ionophore A23187 (5 mM) and significantly less, 15-HETE, 12-HETE, 14-HDHA, and lipoxin A4. Macrophages
from LAP subjects exhibit reduced phagocytosis. The pro-resolving lipid mediator, Resolvin E1 (0.1–100 nM), rescues the
impaired phagocytic activity in LAP macrophages. These abnormalities suggest compromised resolution pathways, which
may contribute to persistent inflammation resulting in establishment of a chronic inflammatory lesion and periodontal
disease progression.
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Introduction
Periodontitis and other periodontal diseases (PD) comprise a
unique and complex group of inflammatory conditions that result
in the destruction of the supporting structures of the dentition [1].
PD is a chronic inflammatory disease initiated by bacterial biofilms
that naturally form on the teeth that is associated with, and is
thought to exacerbate, the symptoms of several inflammatory
disorders such as arthritis, Type II diabetes, preeclampsia,
conditions associated with preterm low birth weight, and
cardiovascular diseases (CVD) [2,3,4,5,6]. PD is a major public
health concern given that it is among the most prevalent human
diseases [7]. Since the pathogenesis of PD has strikingly similar
aspects to many other inflammatory diseases, it has become a
recognized model for examining effector cell mediated inflamma-
tion [8].
The etiology of PD is bacterial plaque and specific Gram-
negative micro-organisms, such as Porphyromonas gingivalis and
Tannerella forsythensis in the case of chronic periodontitis, and
Aggregatobacter actinomycetemcomitans in the case of Localized
Aggressive Periodontitis, are associated with the subgingival
biofilm in disease. [1,9]. The bacteria are necessary, but not
always sufficient to produce disease [10] expression of disease is
associated with modifiable risk factors such as smoking and genetic
risk factors such as the inflammatory response. PD progresses in
periodic, relatively short episodes of rapid tissue destruction
followed by some repair, and prolonged intervening periods of
disease remission [11]. Despite the apparent stochastic distribution
of episodes of disease activity, the resulting tissue breakdown
results in alveolar bone loss and pocket formation, which is
common to several forms of PD. While LAP is clinically distinct
from other types of periodontitis, it seems to represent the extreme
with regard to inflammatory abnormalities. Chronic periodontitis
is also associated with impaired phagocytosis [12] as well as other
hyper-inflammatory traits. LAP is characterized by functional
abnormalities of host cells, particularly neutrophils [13,14] that
possess a hyper-activated or primed phenotype [1,15]. The
functional consequences of neutrophil priming include dysregu-
lated chemotaxis, phagocytic abnormalities, and heightened pro-
inflammatory activity including increased oxidative stress and
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PMN hyperfunction yields its inability to clear bacteria resulting in
tissue damage and chronic lesions [1]. Of note, the cells used in
several of these reports are circulating PMN, not just of those
within the inflammatory milieu. Hyperactive circulating PMN
indicates an underlying systemic component to this disease,
suggesting persistent inflammation that does not resolve.
Resolution of inflammation is crucial for tissue homeostasis and
necessary for ongoing health [19]. Resolution programs require
the local biosynthesis of endogenous specialized pro-resolving lipid
mediators (SPMs). These SPM include the lipoxins, resolvins,
protectins and maresins [19], which are enzymatically synthesized
via sequential steps involving lipoxygenases (LOX), and cycloox-
ygenases (COX). Arachidonic acid (AA) derived Lipoxin A4
(LXA4), as an example, is generated through two distinct
transcellular pathways; a 15-LOX and 5-LOX biosynthetic
pathway or a 5-LOX and 12-LOX pathway [20,21]. Cell: cell
interactions determine the source of the LOX isoforms. The
lipoxygenases are critical enzymes for the formation of LXA4 as
well as the omega-3 EPA and DHA derived resolvins, protectins
are maresins [19]. SPM are dual functioning because they limit
neutrophil accumulation and stimulate non-phlogistic activation of
macrophages in vivo [19,22]. SPM have actions on selective cellular
targets and act via specific G-protein coupled receptors [19]. It is
noteworthy that EPA-derived Resolvin E1 (RvE1) is protective in
several inflammatory disease models, including experimental
periodontitis [8].
Recent evidence suggests that a failure in mounting endogenous
resolution programs may be a key feature in various inflammatory
disorders such as atherosclerosis [23,24]. The mechanisms
underlying failed resolution are not known, but increasing
evidence suggests an imbalance between pro- inflammatory and
pro-resolving mediators to be a factor [25]. Here, we present an
example of a human disease that exhibits a pro-inflammatory
cellular phenotype and a malfunction in the capacity to generate
LXA4 and SPM precursors. LAP has activated circulating platelets
and leukocytes and increased platelet-leukocyte aggregates com-
pared to healthy, asymptomatic controls. There is also an
imbalance in the release pro-inflammatory and anti-inflammatory
LOX-derived lipid mediators from stimulated whole blood of
LAP. Additionally, phagocytosis of opsonized zymosan particles by
LAP macrophages was markedly reduced compared to healthy
controls and RvE1 rescued the impairment. Hence, these results
with LAP suggest an inability to effectively mount resolution
pathways contributing to persistent, non-resolving, chronic lesion
and periodontal disease progression.
Results
LAP has increased platelet–leukocyte aggregates in
whole blood
Platelets, like neutrophils, are key cellular mediators of innate
immune responses [26]. It is known that neutrophils from LAP
patients are primed [27], thus it was of interest to assess whether
platelets in LAP blood are hyperactive as well. Whole blood from
healthy control volunteers or patients diagnosed with LAP was
characterized based on cellular morphology and select antibody
staining (Figure 1A–C). In unstimulated whole blood, platelet P-
selectin was significantly increased (,50%) on the surface of LAP
platelets as compared to healthy control (Figure 1D).
Aberrant formation of platelet-neutrophil and platelet-mono-
cyte aggregates is associated with inflammatory diseases, such as
cardiovascular diseases [28] and chronic periodontitis [29]. Since
P-selectin is increased on LAP platelets, it was of interest to
monitor whether whole blood from LAP donors exhibited
increased platelet-leukocyte aggregates as compared to healthy
control. LAP exhibited significant increases in platelet-PMN and
platelet-monocyte (,50% and ,30% respectively) aggregates
(Figure 1B, E, and C, F respectively) compared to healthy control.
Representative dot plots demonstrate platelet-leukocyte aggregates
where platelets (CD41
+) are represented as green spots from
healthy control (Figure 1B) or LAP (Figure 1C).
Leukocyte recruitment to inflamed areas requires a precise
sequence of events that initially involves the interaction of platelets,
leukocytes and activated endothelial cells via selectins and integrins
[26]. Therefore, here we assessed integrin surface expression on
leukocytes as a marker for activated of leukocytes. LAP exhibited
higher surface expression of CD18 on PMN (Figure 2A, C) and
monocytes (Figure 2B, D) as compared to healthy control.
Representative histograms demonstrate that LAP (black) has a
higher surface expression of CD18 on PMN (Figure 2C) and
monocytes (Figure 2D) as compared to healthy controls (light
gray). Together, these results indicate that LAP resting cells within
whole blood are circulating in a hyperactive or primed state.
Imbalance in LOX biosynthetic markers in LAP
LTB4 and other pro-inflammatory mediators were detected in
the gingival crevicular fluid (GCF) of chronic periodontitis [30]
and LAP patients [31]. We next questioned the pro-inflammatory
and pro-resolving mediator formation within whole blood. To
investigate the capacity of whole blood cells to generate and
release lipid mediators, whole blood was stimulated with A23187
(5 mM) or vehicle, plasma was collected, subjected to solid-phase
extraction followed by LC-MS/MS analysis (Table 1). Represen-
tative donor pairs demonstrated increased LTB4 and 5-HETE
(Figure 3A), and decreased 15-HETE (Figure 3B), 12-HETE
(Figure 3C) and 14-HDHA (Figure 3D) levels plasma obtained
from whole blood of LAP patients with the addition of A23187 (ex
vivo) as compared to healthy controls (Table 1). A representative
chromatogram is shown in Figure 3E. LAP, compared to its age,
gender and race matched asymptomatic controls, has increased 5-
LOX products including LTB4 (47.7%69.8) and 5-HETE
(34.6%67.2) indicating a hyperactive phenotype (Figure 3F). Of
note, 12-LOX and 15-LOX products including 12HETE,
14HDHA and 15-HETE (48.5%617.9, 79.8%65.6, and
43.5%68.5, respectively) were all significantly lower in stimulated
LAP plasma compared to healthy controls (Figure 3F).
Since there is aberrant production of 5-,12-,and 15-LOX
products, it was of interest to investigate the pro-resolving
transcellular biosynthesis product, LXA4. There was significantly
less LXA4 generation (375 pg/mL in healthy controls, 242 pg/mL
in LAP) in A23187-stimulated whole blood of LAP donors
(Figure 3G). These results suggest an imbalance between pro-
inflammatory and pro-resolving mediator generation.
RvE1 Rescues Impaired Phagocytosis in LAP
macrophages
Host defense mechanisms are abnormal in LAP [32].
Macrophages are essential for host defense because of their
capacity to clear cellular debris and pathogens for the eventual
return to homeostasis. LAP macrophage phagocyte function has
not been investigated; therefore, it was of interest to determine
whether LAP has normal phagocytic activity as compared to
healthy control. There were no differences in viability of LAP and
healthy control macrophages after isolation and Wright-Giemsa
staining revealed no apparent difference in morphology between
LAP and healthy control macrophages. Figure 4A demonstrates
that LAP macrophages are impaired at phagocytizing serum
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macrophages to enhance phagocytosis [22,33], it was of interest to
investigate whether RvE1 would rescue the phagocytic defect
observed in LAP. When incubated 15 minutes prior to SZ
addition, RvE1 enhanced phagocytosis in healthy control
(Figure 4B) and LAP macrophages (Figure 4C). Of note, RvE1
as low as 1 nM restored phagocytic activity of LAP macrophages
to levels comparable to healthy controls (Figure 4C). ChemR23,
an RvE1 receptor, has lower surface expression on circulating
monocytes in whole blood (Figure 4 D). These results indicate that
although LAP has impaired phagocytosis, RvE1, when added
exogenously, can rescue the phagocytic defect.
Discussion
Periodontal diseases, such as LAP, result in the inflammatory
destruction of the supporting tissues of the dentition. While the
etiology of periodontitis is bacterial, it is becoming clear that the
pathogenesis of disease is mediated by the host response [34].
Given the essential role of the innate immune system in regulating
immunity, it is conceivable that dysfunction of the components of
resolution can contribute to disease [35]. Hence, it was of interest
to investigate whether distinct cellular and molecular pathways of
resolution from LAP subjects were aberrantly regulated. Here, we
report that (i) LAP platelets, neutrophils and monocytes in whole
Figure 1. LAP platelets and leukocytes in whole blood. Venous whole blood was collected from LAP or healthy control donors. (A) Platelets,
PMN or monocytes were characterized based on positive staining of cell specific antibodies (CD41, CD16, CD14, respectively) and characteristic cell
morphology (representative dot plot). (B,C) Representative dot plots of platelet-leukocyte aggregates. Green spots indicate CD41
+ platelets. (D)
CD41
+CD62P
+ were assessed and quantified via flow cytometry and Cell Quest software (LAP platelets, black bar; healthy control, white bar). (E) PMN
or (F) monocyte populations with CD41
+ staining. Results are mean 6 SEM, n=4, *p,0.05.
doi:10.1371/journal.pone.0024422.g001
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compared to healthy control, as well as increased platelet-
neutrophil and platelet-monocyte aggregates, (ii) the generation
of LXA4 and maresin precursor, 14-HDHA was compromised in
LAP whole blood and (iii) macrophages from LAP patients exhibit
impaired phagocytosis as compared to healthy control.
Inflammation, a common feature of periodontal and cardiovas-
cular diseases [36,37], can be assessed at the cellular level by
investigating the interactions between platelets and leukocytes.
Figure 1 displays significantly elevated levels of P-selectin on
platelets as well as increased platelet-leukocyte aggregates in LAP
subject blood compared to healthy control blood. Since P-selectin
is mobilized to the platelet surface upon activation, our results
suggest that LAP platelets are circulating in a hyperactive state. In
addition, platelets and leukocytes generally aggregate during
inflammation or in a pathological milieu, such as those associated
with CVD. In fact, circulating monocyte-platelet aggregates have
been reported to be an early marker of myocardial infarction [28].
Therefore, the hyperactive state of LAP platelets as well as their
increased association with leukocytes provides a further mecha-
nistic link between periodontal and cardiovascular diseases [37].
To corroborate our finding that leukocytes are circulating in an
activated state, we also profiled pro-inflammatory chemical
mediators. LAP blood produced increased 5-LO products such
as 5-HETE and LTB4 (Figure 3), which is consistent with earlier
reports that demonstrate LTB4 within inflammatory periodontal
exudates. In addition to periodontal disease, elevated LTB4 levels
have also been associated with other non-communicable chronic
inflammatory disease such as atherosclerosis [38]. Patients with
atherosclerosis were found to possess a 5-LO gene variant leading
to increased LTB4 especially when on an omega-6 rich diet [39].
Of note, when these patients were placed on an omega-3 diet,
there was significantly less LTB4 generation [39].
12- and 15-LOX released products were decreased in LAP
stimulated blood as compared to healthy controls (Figure 3). Of
relevance, in a rabbit model of experimental periodontitis,
overexpression of 15-LOX was protective against P. gingivalis
induced bone loss [40]. Importantly, these rabbits were also
resistant to CVD. The protective role of these lipoxygenase-
derived products extends beyond that of periodontal disease
models. In a pre-clinical disease model of atherosclerosis, 12/15
LOX knockout mice displayed increased atherosclerosis as
compared to wild type [23]. 12- and 15- LOX are also critical
enzymes for the biosynthesis of lipoxins. LXA4 is generated via
transcellular biosynthesis between PMN (5-LOX) and platelet (12-
LOX) [20,41] or 15-lipoxygenase (15-LOX) and PMN (5-LOX)
[20] interactions. LXA4 levels were decreased in LAP compared to
healthy control (Figure 3E) most likely due a result of aberrant
activation of 12- or 15-LOX. Decreased generation of LXA4 was
also seen in cystic fibrosis (CF), where CF patients displayed
increased platelet-leukocyte aggregates, yet compromised LXA4
generation compared to healthy controls [25]. Hence, it is possible
Figure 2. LAP patients display activated leukocytes in whole blood as compared to healthy control. CD18 was monitored on (A) PMN or
(B) monocytes in whole blood without the addition of exogenous stimuli from healthy control (white) versus LAP (black). Results are mean 6 SEM,
n=4, *p,0.05. Representative histograms of CD18 surface expression on (C) PMN and (D) monocytes. HC, healthy control, light grey; LAP, solid black;
IgG dark grey.
doi:10.1371/journal.pone.0024422.g002
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lipoxin or other pro-resolving mediators may be an underlying
component of several inflammatory diseases.
Since LAP is an inflammatory disease exacerbated by microbes,
functional phagocytes to clear pathogens is of utmost importance
for the return to homeostasis. Here, we report that LAP
macrophages do not phagocytize opsonized zymosan A as readily
as healthy control (Figure 4). The impairment in phagocytosis of
opsonized zymosan may be attributed to the known polymor-
phisms of Fcc receptors on leukocytes of periodontal disease
patients [42]. Omega-3 EPA-derived RvE1 that rescued the
phagocytic activity of LAP macrophages (Figure 4) was also shown
to enhance efferocytosis in vitro and in vivo [22]. RvE1 was also
reported to be protective on LAP PMN by dampen ingfMLP-
stimulated O2
- release from LAP PMN [8]. RvE1 is protective for
P. gingivalis -induced bone loss in experimental periodontitis [8,43].
Of note, RvE1 is also protective in asthma [44] and acute lung
injury [45] models underscoring its role as regulator of several
inflammatory diseases. Recent work demonstrated that RvE1
initiates direct activation of the ChemR23 receptor on human
macrophages and signals receptor dependent phosphorylation
during phagocytosis of opsonized zymosan [46].
Several investigations suggest that bone loss in PD is linked to an
imbalance between omega-6 and omega-3 fatty acids [47].
Increased levels of omega-6 AA-derived products, including
prostaglandin E2 (PGE2), thromboxane, prostacyclin and leuko-
triene B4 (LTB4) were found in inflamed gingival tissues and
gingival crevicular fluid (GCF) [48,49]. Clinical studies investigat-
ing serum polyunsaturated fatty acid (PUFA) levels in periodontal
disease patients demonstrated that omega-6 fatty acids were higher
in patients with bone loss than in the control group; reduced bone
loss was seen in patients with increased serum omega-3 levels [47].
Additionally, daily supplementation of omega-3 fatty acids showed
a reduction in periodontal disease gingival pocket formation with
an increase of attachment in periodontal disease patients
indicating that omega-3 fatty acids are protective against
inflammatory bone loss [50].
In addition to environmental factors, there is compelling
evidence for genetic components associated with disease progres-
sion in LAP [51] (reviewed in [52]). As mentioned earlier LAP
PMN exhibit a number of functional abnormalities including
impaired chemotaxis, phagocytic abnormalities, and increased
ROS generation to name a few [16,17,18]. As an example, LAP
PMN that display decreased chemotaxis to n-formylated peptides
like fMLP can at least in part be explained by a genetic variants
associated with FPR receptors [53,54]. The phenotypic abnor-
malities presented in this report imply that our patient population
may also have a genetic abnormality pertaining to a deficiency in
the biosynthesis of lipoxygenase pathways involved in the
production of pro-resolving mediators.
Together, these findings demonstrate that cells from LAP
patients present a heightened pro-inflammatory phenotype with a
compromised capacity to generate SPM. LAP has hyperactive
platelets, PMN and monocytes and increased platelet-leukocyte
aggregates in the circulation compared to healthy controls. In
addition, essential host defense mechanisms, such as removal of
pathogens via macrophage phagocytosis are compromised in LAP.
A resolution agonist, RvE1 rescues this critical impairment. In
view of these findings, pro-resolving lipid mediators, such as RvE1
may be of interest for future clinical application in the treatment of
inflammatory diseases like periodontitis.
Materials and Methods
Antibodies and Reagents
Antibodies. Phycoerythrin (PE)-conjugated mouse anti-
human CD62P was obtained from Pharmingen (San Jose, CA)
and mouse anti-human FITC-CD41 from BD Biosciences
(Rockville, MD). (PE)-conjugated mouse anti-human CD18,
FITC-conjugated mouse anti-human CD14, mouse anti-human
CD16, Cy5-conjugated mouse anti-human CD3, and mouse anti-
human CD20 were all purchased from Pharmingen (San Jose,
CA). GM-CSF was obtained from R&D Systems (Minneapolis,
MN), and FITC–zymosan from Saccharomyces cerevisiae was obtained
from Molecular Probes (Carlsbad, CA). Lipoxin A4 ELISA was
purchased from Neogen Corporation (Lexington, KY). RBC Lysis
buffer was purchased from eBioscience (San Diego, CA).
Histopaque 1077 and Zymosan A were purchased from Sigma-
Aldrich (St. Louis, MO).
Whole blood analysis
Human samples were obtained following informed consent
under a Boston University (Boston, MA, USA) Institutional
Review Board. The Boston University IRB approved our study in
writing (protocol number H-23425). Venous blood (1:10 sodium
citrate anticoagulant) was collected from healthy volunteers
(n=10) or patients with a diagnosis of aggressive periodontitis
(LAP), n=10 with no other known disease. All blood donors were
non-smokers, between the age of 19–48 years of age who had
denied taking any non steroidal anti-inflammatory drugs
(NSAIDs) for at least two weeks prior to the experiment. The
LAP subjects were all of African descent and were characterized
by periodontal infection with multiple organisms including
Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, and
a hyper-responsive neutrophil phenotype (elevated fMLP induced
superoxide generation) [8]. Clinically, subjects presented with
Table 1. LAP whole blood LOX capacity versus healthy donors.
Donor Pairs LTB4 20-OH LTB4 5-HETE 15-HETE 12-HETE 14-HDHA
Healthy control 1205.0 393.5 1335.0 365.5 3280.0 2273.6
LAP 2432.9 363.6 1878.3 246.4 2851.5 326.6
Healthy control 2120.4 682.9 4367.4 1057.4 33430.6 6903.4
LAP 5760.6 1191.8 8584.2 660.4 12699.0 107.1
Healthy control 1761.5 369.3 2407.4 839.6 17615.2 1361.1
LAP 2498.8 489.9 3253.3 332.1 5193.6 427.7
*Whole blood (1 mL) was incubated with A23187 (5 mM) for 20 mins, 37uC. Incubations were stopped on ice and plasma was collected for C-18 solid phase extraction
and subjected to LC-MS/MS based lipidomics. Values are represented as pg/sample.
doi:10.1371/journal.pone.0024422.t001
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only [13]. The patients were diagnosed by a licensed periodontist
in the Clinical Research Center of Boston University School of
Dental Medicine. Healthy control donors showed no signs of
periodontal disease and were matched to LAP donor based on
age, sex and race.
Red blood cells were lysed using 16R B CL y s i sb u f f e rd i l u t e d2 5 : 1
with blood for 10 minutes on ice [55]. Direct immunofluorescence
labeling was performed using anti-human CD41 and CD62P, CD16,
CD14, CD20, CD3 in combination with the corresponding isotype
controls to detect platelets, neutrophils, monocytes, B cells and T cells,
respectively. Cells were analyzed via flow cytometry (Becton, Dickinson
Figure 3. LAP whole blood displays Increased capacity for 5-HETE and LTB4 levels, and decreased for 12-HETE, 14-HDHA, 15-HETE
and LXA4. Whole blood was stimulated A23187 (5 mM) for 20 minutes, 37uC. Incubations were stopped on ice and plasma was collected for LC-MS/
MS or ELISA analysis. (A–D) Representative LC-MS/MS quantitation of A23187-stimulated whole blood from healthy control (HC, white bars) and LAP
(black bars) pairs. (E) Representative chromatogram. (F) Percent change of indicated lipid mediators. Results are meant 6 SEM n=3, *p,0.05,
**p,0.01. (G) Percent increase compared to vehicle of LXA4 was analyzed by ELISA. Results are mean 6 SEM, n=10, *p#0.05, healthy control versus
LAP.
doi:10.1371/journal.pone.0024422.g003
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leukocyte aggregates were determined based on double positive
staining for CD41 and corresponding leukocyte marker.
Human whole blood incubations
Freshly prepared blood (1 mL, anticoagulated with Heparin) was
collected and incubated with A23187 (5 mM) for 20 minutes, 37uC.
Incubations were stopped on ice and plasma was immediately
collected by centrifugation (3506g, 5 minutes, 4uC). Two volumes
of cold methanol and deuterated internal standards (PGE2-d4 and
5(S)-HETE-d8) were then added. Samples were taken to C-18 solid
phase extraction. Methyl formate fractions were collected, dried
under nitrogen and subjected to LC-MS/MS [56].
LC-MS/MS-based lipid mediator lipidomics
LC-MS/MS was performed with a Shimadzu LC-20AD HPLC
(ShimadzuScientific Instruments, Columbia, MD) equipped with an
Agilent Eclipse Plus C18 column (4.6 mm650 mm61.8 mm) paired
with an ABI Sciex Instruments 3200 Qtrap linear ion trap triple
quadrupole mass spectrometer (Applied Biosystems, Foster City,
CA). Instrument control and data acquisition were performed using
AnalystTM 1.5 software (Applied Biosystems). The mobile phase
consisted of methanol/water/acetic acid (60/40/0.01; v/v/v) and
was ramped to 80/20/0.01 (v/v/v) after 10 min, 100/0/0.01 (v/v/
v) after 12 min, and 90:10 (v/v/v) after 1.5 minutes to wash and
equilibrate the column. Ion pairs from reported multiple reaction
monitoring (MRM) methods [56] were used for profiling and
quantification of various lipid mediators, including LTB4, 20-OH-
LTB4, 5-HETE, 12-HETE, 15-HETE, and internal standards. The
MRM transitions were LTB4 (335/195), 20-OH-LTB4 (351/195),
5-HETE (319/115), 12-HETE (319/179), 15-HETE (319/219), 14-
HDHA (343/205), PGE2 (351/189), d8-5-HETE (327/116), and
d4-PGE2 (355/193). The criteria used for positive identification of
compounds of interest were matching retention time and matching
of 6 diagnostic ions to synthetic standards. Quantification was
performed using standard calibration curves for each compound,
and recovery was calculated using deuterated internal standards
(PGE2-d4 and 5(S)-HETE-d8) [56]. LXA4 was confirmed by LC-
MS/MS and quantified by ELISA using a ThermoMax microplate
reader (Molecular Devices, Sunnyvale, CA).
Macrophage Phagocytosis of opsonized FITC-zymosan
Macrophage phagocytosis experiments were carried out as in
[57]. Briefly, monocytes were isolated from human whole blood
Figure 4. LAP Macrophages display impaired phagocytosis of opsonized zymosan particles. Monocytes were collected from venous
whole blood and differentiated into macrophages in the presence of GMCSF (10 ng/mL) for 7 days. After differentiation macrophages were incubated
with vehicle or RvE1 (0.1–100 nM) for 15 minutes. Phagocytosis was carried out for 30 minutes, 37uC and analyzed by a Victor3 fluorescent plate
reader. (A) Healthy control (white bar) and LAP (black bar) baseline phagocytosis. RvE1 (0.1–100 nM) dose response, (B) HC (C) LAP. (D) Monocytes in
whole blood were stained with anti-human ChemR23 and analyzed by flow cytometry. Results are mean 6 SEM, n=4, *p,0.05.
doi:10.1371/journal.pone.0024422.g004
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for 7 days. Macrophages were enumerated in a hemocytometer
and viability was determined by Trypan blue exclusion. For
phagocytosis of serum-opsonized zymosan A (SZ) experiments,
macrophages (0.1610
6 cells/well in a 24-well plate) were
incubated with RvE1 or vehicle for 15 min at 37uC. FITC–SZ
from Saccharomyces cerevisiae was then added to cells (0.5610
6
particles/well) and incubated (30 min at 37uC) in the dark.
Supernatants were aspirated, and Trypan blue (0.03% in PBS+/+
for ,60 s) was added to quench extracellular FITC–STZ.
Fluorescence was measured using a Victor plate reader (Perki-
nElmer).
Data analysis
The significance of difference between groups was evaluated
using the 2-tailed Student’s t-test. P values of less than 0.05 were
considered to be statistically significant.
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